参考文献/References:
[1] Silva AI,de Matos AN,Brons IG,et al.An overview on the development of a bio-artificial pancreas as a treatment of insulin-dependent diabetes mellitus[J].Med Res Rev,2006,26(2):181-222.DOI:10.1002/med.20047.
[2] Vantyghem MC,Chetboun M,Gmyr V,et al.Ten-year outcome of islet alone or islet after kidney transplantation in type 1 diabetes:a prospective Parallel-Arm cohort study[J].Diabetes Care,2019,42(11):2042-2049.DOI:10.2337/dc19-0401.
[3] Ravi PK,Purkait S,Agrawal U,et al.Regional variation of human pancreatic islets dimension and its impact on beta cells in Indian population[J].Islets,2019,11(6):141-151. DOI:10.1080/19382014.2019.1686323.
[4] Wang L,Gao P,Zhang M,et al.Prevalence and ethnic pattern of diabetes and prediabetes in china in 2013[J].JAMA,2017,317(24):2515-2523.DOI:10.1001/jama.2017.7596.
[5] Kin T,Murdoch TB,Shapiro AM,et al.Estimation of pancreas weight from donor variables[J].Cell Transplant,2006,15(2):181-185.DOI:10.3727/000000006783982133.
[6] Nano R,Clissi B,Melzi R,et al.Islet isolation for allotransplantation:variables associated with successful islet yield and graft function[J].Diabetologia,2005,48(5):906-912.DOI:1007/s00125-005-1725-3.
[7] Hanley SC,Paraskevas S,Rosenberg L.Donor and isolation variables predicting human islet isolation success[J].Transplantation,2008,85(7):950-955.DOI:10.1097/TP.0b013e3181683df5.
[8] Proneth A,Schnitzbauer AA,Zeman F,et al.Extended pancreas donor program-the EXPAND study rationale and study protocol[J].Transplant Res,2013,2(1):12.DOI:210.1186/2047-1440-2-12.
[9] Vinkers MT,Rahmel AO,Slot MC,et al.How to recognize a suitable pancreas donor:a Eurotransplant study of preprocurement factors[J].Transplant Proc,2008,40(5):1275-1278.DOI:10.1016/j.transproceed.2008.03.142.
[10] Verma M, Rajput M,Kishore K,et al.Asian BMI criteria are better than WHO criteria in predicting Hypertension:A cross-sectional study from rural India[J].J Family Med Prim Care, 2019,8(6):2095-2100.DOI:10.4103/jfmpc.jfmpc_257_19.
[11] Matsumoto I,Sawada T,Nakano M,et al.Improvement in islet yield from obese donors for human islet transplants[J].Transplantation,2004,8(6):880-885.DOI:10.1097/01.tp.0000134396.03440.1e.
[12] Hilling DE,Bouwman E,Terpstra OT,et al.Effects of donor-,pancreas-,and isolation-related variables on human islet isolation outcome:a systematic review[J].Cell Transplant,2014,23(8):921-928.DOI:10.3727/096368913X666412.
[13] Wang LJ,Kin T,O'Gorman D,et al.A multicenter study:north american islet donor score in donor pancreas selection for human islet isolation for transplantation[J].Cell Transplant,2016,25(8):1515-1523.DOI:10.3727/096368916X691141.
[14] Wang Y,Danielson KK,Ropski A,et al.Systematic analysis of donor and isolation factor's impact on human islet yield and size distribution[J].Cell Transplant,2013,22(12):2323-2333.DOI:10.3727/096368912X662417.
[15] Ponte GM,Pileggi A,Messinger S,et al.Toward maximizing the success rates of human islet isolation:influence of donor and isolation factors[J].Cell Transplant,2007,16(6):595-607.DOI:10.3727/000000007783465082.
[16] Brandhorst H,Brandhorst D,Hering BJ,et al.Body mass index of pancreatic donors:a decisive factor for human islet isolation[J].Exp Clin Endocrinol Diabetes,1995,103 Suppl 2:23-26.DOI:10.1055/s-0029-1211388.
[17] Charles ED,Neuschwander-Tetri BA,Pablo Frias J,et al.Pegbelfermin(BMS-986036),PEGylated FGF21,in patients with obesity and type 2 diabetes:results from a randomized phase 2 study[J].Obesity(Silver Spring),2019,27(1):41-49.DOI:10.1002/oby.22344.
[18] Linnemann AK,Baan M,Davis DB.Pancreatic β-cell proliferation in obesity[J].Adv Nutr,2014,5(3):278-288.DOI:10.3945/an.113.005488.
[19] Dollerup OL,Trammell SAJ,Hartmann B,et al.Effects of nicotinamide riboside on endocrine pancreatic function and incretin hormones in nondiabetic men with obesity[J].J Clin Endocrinol Metab,2019,104(11):5703-5714.DOI:10.1210/jc.2019-01081.
[20] Liu T,Sun P,Zou J,et al.Increased frequency of β cells with abnormal NKX6.1 expression in type 2 diabetes but not in subjects with higher risk for type 2 diabetes[J].BMC Endocr Disord,2021,21(1):47.DOI:10.1186/s12902-021-00708-7.
相似文献/References:
[1]刘璐,李鸿.代谢调控的新靶点——Irisin[J].国际内分泌代谢杂志,2014,(02):109.[doi:10.3760/cma.j.issn.1673-4157.2014.02.011]
Liu Lu,Li Hong..A new target in metabolic control--Irisin[J].International Journal of Endocrinology and Metabolism,2014,(05):109.[doi:10.3760/cma.j.issn.1673-4157.2014.02.011]
[2]李爱玲,谢云,李瑾,等.体重指数和腰臀比预测非酒精性脂肪性肝病发病风险的比较[J].国际内分泌代谢杂志,2014,(02):135.[doi:10.3760/cma.j.issn.1673-4157.2014.02.018]
Li Ailing,Xie Yun,Li Jin,et al.Comparison of body mass index and waist-to-hip ratio for predicting of non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2014,(05):135.[doi:10.3760/cma.j.issn.1673-4157.2014.02.018]